drugset
drugset / Trial / NCT00684970

Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)

NCT00684970 ↗

Phase 2 Unknown 100 enrolled Tiltan Pharma Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety.The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic Castration Resistant Prostate Cancer (CRPC) patients.

Timeline

Start
2009-03
Primary completion
2014-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Hamsa-1™ Unknown — Oral

Indications

prostate carcinoma